MKI67 and adrenal cortex carcinoma: There are currently ongoing clinical trials (ADIUVO‐2 trial, ClinicalTrials.gov identifier: NCT03583710) for adjuvant treatment of high‐risk cases (stage I–III and Ki‐67 PI >10%) of ACC with mitotane alone and mitotane plus cisplatin and etoposide, with the results expected around 2025.